BNP Paribas Analysts Give AstraZeneca (AZN) a GBX 6,500 Price Target

AstraZeneca (LON:AZN) has been assigned a GBX 6,500 ($84.67) price target by equities researchers at BNP Paribas in a research report issued on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. BNP Paribas’ price objective indicates a potential upside of 13.28% from the stock’s previous close.

A number of other analysts have also recently commented on the company. Kepler Capital Markets upped their price target on AstraZeneca from GBX 5,630 ($73.34) to GBX 6,100 ($79.46) and gave the company a “buy” rating in a research note on Friday. Jefferies Financial Group cut AstraZeneca to a “hold” rating and lowered their price target for the company from GBX 6,200 ($80.76) to GBX 5,975 ($77.83) in a research note on Friday. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research note on Friday. Goldman Sachs Group set a GBX 4,080 ($53.15) price target on AstraZeneca and gave the company a “sell” rating in a research note on Friday, August 31st. Finally, Liberum Capital reaffirmed a “hold” rating on shares of AstraZeneca in a research note on Friday, August 31st. Three research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of GBX 5,674.71 ($73.92).

Shares of AZN stock traded up GBX 35 ($0.46) on Tuesday, reaching GBX 5,738 ($74.74). The company had a trading volume of 649,392 shares, compared to its average volume of 2,310,000. AstraZeneca has a 12 month low of GBX 4,260 ($55.49) and a 12 month high of GBX 5,520 ($71.90).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: What are the most popular ETFs

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.

Leave a Reply